Ableitung von HBM-I-Werten für Perfluoroktansäure (PFOA) und Perfluoroktansulfonsäure (PFOS) – Stellungnahme der Kommission „Humanbiomonitoring“ des Umweltbundesamts

Umweltbundesamt,

doi:10.1007/s00103-018-2709-z

Cited by 15 publications

(2 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk assessments of perfluoroalkyls or PFOA from EFSA (Knutsen et al, 2018), US-EPA (US-EPA, 2016), UBA (Umweltbundesamt, 2018), and RIVM (RIVM, 2016) were selected for analysis. The PDAT was applied to analyze the argumentation for the selection of health endpoints of concern; to infer causality between exposure to PFOA and selected adverse health effects and the choice of toxicological or epidemiological data.…”

Section: Methodsmentioning

confidence: 99%

“…In this article, the consideration of toxicological and epidemiological data in the actual practice of risk assessment is analyzed using argumentation analysis, without reviewing the derivation of the HBGV itself. Because argumentation analysis is laborious and time-consuming, our analysis is limited to one chemical (PFOA) and to risk assessments of the Dutch National Institute for Public Health and the Environment (RIVM), the European Food and Safety Authority (EFSA), the Umweltbundesamt (UBA) and the United Stated Environmental Protection Agency (US-EPA) of the perfluoroalkyl compound perfluorooctanoic acid (PFOA) (Knutsen et al, 2018;RIVM, 2016;Umweltbundesamt, 2018;US-EPA, 2016). Past and present exposures to perfluoralkyls via the environment have raised concern among residents in the United States of America and Europe about possible adverse health effects.…”

Section: Othermentioning

confidence: 99%

See 1 more Smart Citation

Argumentation Analysis of Risk Assessments: The Case of Perfluorooctanoic Acid

et al. 2021

View full text Add to dashboard Cite

Risk assessment of chemicals can be based on toxicology and/or epidemiology. The choice of toxicological or epidemiological data can result in different health-based guidance values (HBGVs). Communicating the underlying argumentation is important to explain these differences to the public and policymakers. In this article, we explore the argumentation used to justify the use of toxicological or epidemiological data in the derivation of HBGVs in four different risk assessments for the chemical Perfluorooctanoic acid (PFOA). The pragmadialectical argumentation theory (PDAT) is hereby applied. The argumentations to select relevant health endpoints or certain studies to infer causality appeared mainly based on "symptomatic relations," that is, study results are used as characteristic of what was claimed to be a causal relation without delving into the actual causal argumentation that preceded it. Starting points that are at the basis of the chain of arguments remained implicit. Argumentation to use epidemiological and/or toxicological data was only briefly mentioned and the underlying argumentative foundation that led to the conclusion was seldom found or not addressed at all. The decision to include/exclude information was made based on the availability of data, or the motives for the choice remained largely unclear. We conclude that more depth in argumentation and a subordinative chain of arguments is needed to better disclose the underlying reasoning leading to a certain health-based guidance value (HBGV). More explicit identification and discussion of starting points could be a valuable addition to general risk assessment frameworks for maximum use of toxicological and epidemiological data and shared conclusions of the assessment.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Othermentioning

confidence: 99%

Argumentation Analysis of Risk Assessments: The Case of Perfluorooctanoic Acid

et al. 2021

View full text Add to dashboard Cite

show abstract

Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEElevated levels of blood perfluoroalkyl and polyfluoroalkyl substances (PFASs) have been associated with a range of adverse health outcomes. Firefighters have been exposed to PFASs in firefighting foams and have previously been shown to have higher PFAS levels in blood samples than the general population. No interventions have been shown to reduce PFAS levels. OBJECTIVE To examine the effect of blood or plasma donations on PFAS levels in firefighters in Australia. DESIGN, SETTING, AND PARTICIPANTS This 52-week, open-label, randomized clinical trial enrolled participants from May 23 to August 23, 2019. Participants were 285 Fire Rescue Victoria staff orcontractors with serum levels of perfluorooctane sulfonate (PFOS) of 5 ng/mL or more who were eligible to donate blood, had not donated blood in the 3 months prior to randomization, and were able to provide written informed consent. Analysis was performed on an intention-to-treat basis from May to July 2021. INTERVENTIONSFirefighters with baseline PFOS levels of 5 ng/mL or more were randomly assigned to donate plasma every 6 weeks for 12 months, donate blood every 12 weeks for 12 months, or be observed only. MAIN OUTCOMES AND MEASURESThe primary end points were changes in the serum PFOS and perfluorohexane sulfonic acid (PFHxS) levels after 12 months of plasma or blood donations or after observation only. Secondary end points included changes in serum PFAS levels from week 52 to week 64, changes in other PFASs, and changes in complete blood count, biochemistry, thyroid function, and lipid profile from screening to week 52. RESULTSA total of 285 firefighters (279 men [97.9%]; mean [SD] age, 53.0 [8.4] years) were enrolled; 95 were randomly assigned to donate plasma, 95 were randomly assigned to donate blood, and 95 were randomly assigned to be observed. The mean level of PFOS at 12 months was significantly reduced by plasma donation (-2.9 ng/mL; 95% CI, -3.6 to -2.3 ng/mL; P < .001) and blood donation (-1.1 ng/mL; 95% CI, -1.5 to -0.7 ng/mL; P < .001) but was unchanged in the observation group. The mean level of PFHxS was significantly reduced by plasma donation (-1.1 ng/mL; 95% CI, -1.6 to -0.7 ng/mL; P < .001), but no significant change was observed in the blood donation or observation groups. Analysis between groups indicated that plasma donation had a larger treatment effect than blood donation, but both were significantly more efficacious than observation in reducing PFAS levels. (continued) Key Points Question Can levels of perfluoroalkyl and polyfluoroalkyl substances (PFASs) in the blood be reduced by blood or plasma donations? Findings In this randomized clinical trial of 285 firefighters, both blood and plasma donations resulted in significantly lower PFAS levels than observation alone. Plasma donation was the most effective intervention, reducing mean serum perfluorooctane sulfonate levels by 2.9 ng/mL compared with a 1.1-ng/mL reduction with blood donation, a significant difference; similar changes were seen with other PFASs. Meaning Blood or pl...

show abstract

HBM-II-Werte für Perfluoroctansäure (PFOA) und Perfluoroctansulfonsäure (PFOS) in Blutplasma – Stellungnahme der Kommission Human-Biomonitoring des Umweltbundesamtes

2020

Bundesgesundheitsbl

View full text Add to dashboard Cite

Ableitung von HBM-I-Werten für Perfluoroktansäure (PFOA) und Perfluoroktansulfonsäure (PFOS) – Stellungnahme der Kommission „Humanbiomonitoring“ des Umweltbundesamts

Cited by 15 publications

References 109 publications

Argumentation Analysis of Risk Assessments: The Case of Perfluorooctanoic Acid

Argumentation Analysis of Risk Assessments: The Case of Perfluorooctanoic Acid

Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia

HBM-II-Werte für Perfluoroctansäure (PFOA) und Perfluoroctansulfonsäure (PFOS) in Blutplasma – Stellungnahme der Kommission Human-Biomonitoring des Umweltbundesamtes

Contact Info

Product

Resources

About